AstraZeneca (AZN) -Oxford vaccine prevents 79% of Covid cases, US Data Show

AstraZeneca (AZN) -Oxford vaccine prevents 79% of Covid cases, US Data Show

AstraZeneca Plc’s coronavirus vaccine performed better than expected in a US clinical trial, which provided reassurance about its safety and efficacy.

The plan developed with the Oxford University was 79% effective in preventing Covid-19, and an independent oversight committee found no safety concerns, the company said Monday. All immunized people were protected against serious illness and death in a study involving more than 30,000 volunteers.

The results should boost confidence in the vaccine after confusion over its effectiveness and the best dosing regimen slowed intake. The product is at the center of a supply standoff with the European Union just days after concerns over blood clots prompted a dozen member states to suspend vaccinations. Even after the The European Medicines Agency declared it safe last Thursday, not all EU countries have resumed vaccinations.

“Efficiency is better than we expected,” said Peter Welford, analyst at Jefferies in London. “Importantly, after recent largely unfounded security concerns in Europe, the study confirms the security profile.”

Read more: EU regulator considers Astra safe, but recommends warning label

Astra shares rose 1.4% in London trading. The company said it plans to submit the test data to US regulators in the coming weeks, in order to obtain clearance for an emergency use authorization.

Data confusion

Insufficient deliveries to the EU have put Astra disagrees with the bloc and has led officials to oppose the region’s shooting exports as they sought to hold the company to account.

Read more: Vaccine battle heats up with EU poised to halt UK shipments

The new data offers more clarity than the first results of the study published last November. These clinical trials, conducted in the UK and Brazil, produced a range of readings due to the different dosage amounts and regimens used. At least 10 EU countries only approved the vaccine for those under 65 to start with, as early trials lacked older participants. Many have since reversed course after more real-world usage data showed the vaccine to work for everyone.

Older adults made up about one-fifth of the US trial, which showed 80% effectiveness in this age group. The results “confirm that adults of all ages can benefit from protection against the virus,” Ann Falsey, professor at the The University of Rochester School of Medicine and one of the trial’s lead investigators, said in a statement.


Please enter your comment!
Please enter your name here